This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-09-1086v1 69/15/6021    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Cullen, M. Articles by St. Croix, B. PubMed PubMed Citation Articles by Cullen, M. Articles by St. Croix, B.

Host-Derived Tumor Endothelial Marker 8 Promotes the Growth of Melanoma

¹ Tumor Angiogenesis Section, Mouse Cancer Genetics Program, ² Basic Research Program, Science Applications International Corporation, ³ Pathology/Histotechnology Laboratory, Science Applications International Corporation, and ⁴ Mouse Cancer Genetics Program, National Cancer Institute-Frederick, Frederick, Maryland

Requests for reprints: Brad St. Croix, National Cancer Institute-Frederick, Building 560, P. O. Box B, Frederick, MD 21702-1201. Phone: 301-846-7456; Fax: 301-846-7017; E-mail: stcroix{at}ncifcrf.gov.

Key Words: angiogenesis • endothelial • TEM8

Tumor endothelial marker 8 (TEM8) was initially identified as a gene overexpressed in the vasculature of human tumors and was subsequently identified as an anthrax toxin receptor. To assess the functional role of TEM8, we disrupted the TEM8 gene in mice by targeted homologous recombination. TEM8^–/– mice were viable and reached adulthood without defects in physiologic angiogenesis. However, histopathologic analysis revealed an excess of extracellular matrix in several tissues, including the ovaries, uterus, skin, and periodontal ligament of the incisors, the latter resulting in dental dysplasia. When challenged with B16 melanoma, tumor growth was delayed in TEM8^–/– mice, whereas the growth of other tumors, such as Lewis lung carcinoma, was unaltered. These studies show that host-derived TEM8 promotes the growth of certain tumors and suggest that TEM8 antagonists may have utility in the development of new anticancer therapies. [Cancer Res 2009;69(15):6021–6]